Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Mysoline
Synonyms :
primidone
Class :
Barbiturate anticonvulsants
Brand Name :
Mysoline
Synonyms :
primidone
Class :
Barbiturate anticonvulsants
Dosage Forms & Strengths
Tablet
50mg
250mg
Initially:
100 - 125
mg
Orally 
at bedtime
3
days
then 100-125 mg twice a day for 3 days
following 100-125 mg thrice a day for 3 days, then 250 mg thrice to four times a day; without exceeding 2 g/day
Dose Adjustments
Dosing considerations:
Should not exceed more than 2 g/day
Do not stop abruptly, due to the chances of risk to status epilepticus
Therapeutic efficacy may take several weeks to achieve
Tablet
50mg
250mg
Refer to adult dosing
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may decrease the levels of serum concentration of maribavir
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with cannabinoid products
may diminish the concentration of serum when combined with cannabinoid products
CYP3A4 Inducers: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inducers: they may diminish the serum concentration of hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
primidone: they may diminish the serum concentration of canagliflozin
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may increase the action of CNS depressants inducing CNS depression
bunazosin (Not available in the United States)
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of primidone
may diminish the serum concentration of primidone
may diminish the serum concentration of primidone
may enhance serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 Inducers
may increase the CNS depressant effect of primidone
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may decrease the serum concentration when combined with CYP3A4 Inducers (Strong)
may increase or decrease the activity of this enzyme when combined with sparsentan
may diminish the serum concentration when combined with alfentanil
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with aripiprazole
may diminish serum concentrations when combined with aripiprazole lauroxil
may diminish the serum concentration when combined with atogepant
may diminish the serum concentration when combined with belumosudil
may diminish the serum concentration when combined with brexpiprazole
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with fenfluramine
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
clopidogrel: they may enhance serum concentrations of CYP2C19 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
diltiazem: they may diminish the serum concentration of CYP3A4 Inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
CYP3A4 inducers: they may diminish the serum concentration of eravacycline
erlotinib: they may diminish the serum concentration of CYP3A4 inducers
etoposide: they may diminish the serum concentration of CYP3A4 inducers
exemestane: they may diminish the serum concentration of CYP3A4 Inducers
felodipine: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 inducers: they may diminish the serum concentration of ganaxolone
may increase the CNS depressant effect of Buprenorphine
may diminish the serum concentration of zanubrutnib
drospirenone/ethinyl estradiol/levomefolateÂ
may diminish the serum concentration of Hormonal Contraceptives
buprenorphine,long-acting injectionÂ
may increase the CNS depressant effect of Buprenorphine
may diminish the serum concentration of Voxelotor
brigatinib: they may diminish the serum concentration of CYP3A4 Inducers
daclatasvir: they may diminish the serum concentration of CYP3A4 Inducers
erdafitinib: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of larotrectinib
lefamulin: they may diminish the serum concentration of CYP3A4 Inducers
lorlatinib: they may increase the hepatotoxic effect of CYP3A4 Inducers
lurasidone: they may diminish the serum concentration of CYP3A4 Inducers
maraviroc: they may diminish the serum concentration of CYP3A4 Inducers
mitapivat: they may diminish the serum concentration of CYP3A4 Inducers
perampanel: they may diminish the serum concentration of CYP3A4 Inducers
pirtobrutinib: they may diminish the serum concentration of CYP3A4 Inducers
praziquantel: they may diminish the serum concentration of CYP3A4 Inducers
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the concentration of serum when combined with methylprednisolone
may diminish the serum concentration of Hormonal Contraceptives
etonogestrel/ethinyl estradiolÂ
may diminish the serum concentration of Hormonal Contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with indinavir
ranolazine: they may enhance the serum concentration of CYP3A4 Inducers
sirolimus: they may enhance the serum concentration of CYP3A4 Inducers
triazolam: they may enhance the serum concentration of CYP3A4 Inducers
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
simvastatin: it may diminish the serum concentration of CYP3A4 Inducers
it decreases the concentration of rilpivirine in the serum
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
may diminish the concentration of serum when combined with antihepaciviral products
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
relugolix/estradiol/norethindrone
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
primidone decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
may increase the levels of each other by decreasing the metabolism
may reduce the therapeutic effect of hemin
may reduce the level of serum concentration of abemaciclib
methyldopa/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of primidone
may diminish serum concentrations of CYP3A4 inducers
may enhance the serum concentration when combined with CYP3A4 substrates
they decrease the concentration of glasdegib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
may enhance the serum concentration when combined with CYP3A4 substrates
may enhance the serum concentration of elbasvir/grazoprevir
it increases the concentration of CYP3A4 substrates in the serum
may diminish the serum concentration when combined with tolvaptan
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of avapritinib
CYP3A4 Inducers: they may diminish the serum concentration of capmatinib
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
they decrease the concentration of lurbinectedin in the serum
may diminish the concentration of serum when combined with lemborexant
may enhance the concentration of serum when combined with CYP3A4 substrates
may enhance the concentration of serum when combined with CYP3A4 substrates
naxitinib: they may diminish the serum concentration of CYP3A4 Inducers
bosutinib: they may diminish the serum concentration of CYP3A4 Inducers
cariprazine: they may diminish the serum concentration of CYP3A4 Inducers
cobimetinib: they may diminish the serum concentration of CYP3A4 Inducers
daridorexant: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of elacestrant
encorafenib: they may diminish the serum concentration of CYP3A4 Inducers
fedratinib: they may diminish the serum concentration of CYP3A4 Inducers
finerenone: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
ibrexafungerp: they may diminish the serum concentration of CYP3A4 Inducers
ivabradine: they may diminish the serum concentration of CYP3A4 Inducers
lenacapavir: they may diminish the serum concentration of CYP3A4 Inducers
leniolisib: they may diminish the serum concentration of CYP3A4 Inducers
mavacamten: they may diminish the serum concentration of CYP3A4 Inducers
neratinib: they may diminish the serum concentration of CYP3A4 Inducers
olaparib: they may diminish the serum concentration of CYP3A4 Inducers
olutasidenib: they may diminish the serum concentration of CYP3A4 Inducers
omaveloxolone: they may diminish the serum concentration of CYP3A4 Inducers
pemigatinib: they may diminish the serum concentration of CYP3A4 Inducers
rimegepant: they may diminish the serum concentration of CYP3A4 Inducers
selumetinib: they may diminish the serum concentration of CYP3A4 Inducers
sertraline: they may diminish the serum concentration of CYP3A4 Inducers
tazemetostat: they may diminish the serum concentration of CYP3A4 Inducers
ulipristal: they may diminish the serum concentration of CYP3A4 Inducers
venetoclax: they may diminish the serum concentration of CYP3A4 Inducers
voclosporin: they may diminish the serum concentration of CYP3A4 Inducers
vonoprazan fumarate: they may enhance the serum concentration of CYP3A4 Inducers
vorapaxar: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the concentration of serum when combined with isavuconazonium sulfate
may diminish the serum concentration when combined
may diminish the concentration of serum when combined with antihepaciviral products
may diminish the concentration of serum when combined with axitinib
may diminish the concentration of serum when combined with dasabuvir
may diminish the concentration of serum when combined with entrectinib
they decrease the concentration of active metabolites of tamoxifen in serum
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
may reduce the level of serum concentration of estrogen drugs
bazedoxifene/conjugated estrogens
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
It may enhance the metabolism when combined with dexamethasone
may have an increased hypotensive effect when combined with antihypertensive agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
It may diminish the effects when combined with vitamin D
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
it may diminish the metabolism when combined with diosmin
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
May diminish the effects of pharmacodynamic antagonism
May diminish the effects of pharmacodynamic antagonism
May diminish the effects of pharmacodynamic antagonism
May diminish the effects of pharmacodynamic antagonism
May diminish the effects of pharmacodynamic antagonism
may decrease the levels by unspecified interaction mechanism
may decrease the levels by unspecified interaction mechanism
may decrease the levels by unspecified interaction mechanism
may decrease the levels by unspecified interaction mechanism
may decrease the levels by unspecified interaction mechanism
may increase the risk of sedation
may increase the risk of sedation
may increase the risk of sedation
may increase the risk of sedation
may increase the risk of sedation
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
is having an antagonistic impact over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
valproate increases the concentration of serum barbiturates in the serum
may increase the hypotensive effect of antihypertensives
may increase the hypotensive effect
may increase the hypotensive effect of anti-hypertensives
may increase the hypotensive effect of blood pressure-lowering agents
hydrochlorothiazide/aliskirenÂ
may increase the hypotensive effect of blood pressure-lowering agents
may increase the hypotensive effect of blood pressure-lowering agents
lisinopril/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
eprosartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
valsartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
may enhance the metabolism of primidone
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may enhance the serum concentration when combined with CYP3A4 substrates
may enhance serum concentrations when combined with doxercalciferol
may decrease the level of serum concentrations of itraconazole
may diminish the serum concentration when combined with selpercatinib
may diminish the serum concentration when combined with nimodipine
may diminish the serum concentration when combined with upadacitinib
may have an increased hepatotoxic effect when combined with primidone
may reduce the levels of serum concentration of tivozanib
may increase the hypotensive effect of blood pressure-lowering agents
may diminish the serum concentration of lidocaine
may increase the hypotensive effect of Blood Pressure Lowering Agents
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with ziprasidone
may increase the hypotensive effect of Blood Pressure Lowering Agents
may enhance the serum concentration when combined
eszopiclone: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
hydrocodone: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
meperidine: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
may increase the hypotensive effect of Blood Pressure Lowering Agents
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may enhance the serum concentration of Buprenorphine
estrogens esterified/methyltestosterone            Â
may diminish the serum concentration when combined
may enhance the concentration of serum when combined with fluticasone
aprepitant: they may diminish the serum concentration of CYP3A4 Inducers
codeine: they may diminish serum concentrations of CYP3A4 Inducers
copanlisib: they may diminish the serum concentration of CYP3A4 Inducers
omeprazole: they may diminish the serum concentration of CYP2C19 Inducers
diazepam: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
eliglustat: they may diminish the serum concentration of CYP3A4 Inducers
elvitegravir: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
fentanyl: they may diminish the serum concentration of CYP3A4 Inducers
ibrutinib: they may diminish the serum concentration of CYP3A4 Inducers
idelalisib: they may diminish the serum concentration of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
imatinib: they may diminish the serum concentration of CYP3A4 Inducers
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
istradefylline: they may diminish the serum concentration of CYP3A4 inducers
lapatinib: they may diminish the serum concentration of CYP3A4 Inducers
lercanidipine: they may diminish the serum concentration of CYP3A4 Inducers
levamlodipine: they may diminish the serum concentration of CYP3A4 Inducers
mianserin: they may diminish the serum concentration of CYP3A4 Inducers
midazolam: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the concentration of serum when combined with taurursodiol
midostaurin: they may diminish the serum concentration of CYP3A4 Inducers
naldemedine: they may diminish the serum concentration of CYP3A4 Inducers
naloxegol: they may diminish the serum concentration of CYP3A4 Inducers
nilvadipine: they may diminish the serum concentration of CYP3A4 Inducers
osimertinib: they may diminish the serum concentration of CYP3A4 Inducers
oxycodone: they may diminish the serum concentration of CYP3A4 Inducers
prednisolone: they may diminish the serum concentration of CYP3A4 Inducers
prednisone: they may diminish the serum concentration of CYP3A4 Inducers
quetiapine: they may diminish the serum concentration of CYP3A4 Inducers
quinidine: they may diminish the serum concentration of CYP3A4 Inducers
quinine: they may diminish the serum concentration of CYP3A4 Inducers
regorafenib: they may diminish the serum concentration of CYP3A4 Inducers
repaglinide: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
samidorphan: they may diminish the serum concentration of CYP3A4 Inducers
sildenafil: they may diminish the serum concentration of CYP3A4 Inducers
sorafenib: they may diminish the serum concentration of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
ticagrelor: they may diminish serum concentrations of CYP3A4 Inducers
tofacitinib: they may diminish the serum concentration of CYP3A4 Inducers
toremifene: they may diminish serum concentrations of CYP3A4 Inducers
trabectedin: they may diminish the serum concentration of CYP3A4 Inducers
tramadol: they may diminish the serum concentration of CYP3A4 Inducers
trazodone: they may diminish the serum concentration of CYP3A4 Inducers
tucatinib: they may diminish the serum concentration of CYP3A4 Inducers
vemurafenib: they may diminish the serum concentration of CYP3A4 Inducers
verapamil: they may diminish the serum concentration of CYP3A4 Inducers
vilazodone: they may diminish the serum concentration of CYP3A4 Inducers
zolpidem: they may diminish the serum concentration of CYP3A4 Inducers
zopiclone: they may diminish the serum concentration of CYP3A4 Inducers
may decrease the concentration of serum when combined with methylergometrine
may increase the hypotensive effect of Blood Pressure Lowering Agents
may diminish the serum concentration of each other when combined
may diminish the concentration of serum when combined with artemether and lumefantrine
may diminish the concentration of serum when combined with atazanavir
benzhydrocodone/acetaminophenÂ
may diminish the concentration of serum when combined with benzhydrocodone
may decrease the hypotensive effect of Blood Pressure Lowering Agents
it decreases the concentration of CYP3A4 inducers in serum
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Anticonvulsants
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine 13-valent
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine heptavalent
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine polyvalent
It may enhance the risk of adverse effects when combined with Hypnotics
It may enhance the risk of adverse effects when combined with CYP3A4 inducers
rolapitant: they may diminish the serum concentration of CYP3A4 Inducers
may increase the hypotensive effect of barbiturates
nicardipine: they may diminish the serum concentration of CYP3A4 Inducers
dapoxetine: they may diminish the serum concentration of CYP3A4 Inducers
brimonidine: they may diminish the serum concentration of CYP3A4 Inducers
cimetidine: they may diminish the serum concentration of CYP3A4 Inducers
diazoxide: they may diminish the serum concentration of CYP3A4 Inducers
flunarizine: they may diminish the serum concentration of CYP3A4 Inducers
melatonin: they may diminish the serum concentration of CYP3A4 Inducers
methylphenidate: they may diminish the serum concentration of CYP3A4 Inducers
molsidomine: they may diminish the serum concentration of CYP3A4 Inducers
atosiban: they may diminish the serum concentration of CYP3A4 Inducers
alfuzosin: they may diminish the serum concentration of CYP3A4 Inducers
dimercaprol: they may diminish the serum concentration of CYP3A4 Inducers
cannabis: they may enhance the serum concentration of CYP3A4 inducers
propofol: they may enhance the serum concentration of CYP3A4 inducers
tacrolimus: they may enhance the serum concentration of CYP3A4 Substrates
warfarin: they may enhance the serum concentration of CYP3A4 inducers
tricyclic antidepressants: they may enhance the serum concentration of CYP3A4 inducers
cannabinoid receptor agonists: they may enhance the serum concentration of CYP3A4 inducers
cannabinoid receptor agonists: they may enhance the serum concentration of CYP3A4 inducers
an increase in CNS depression may be seen
an increase in rate of metabolism may be seen
cinnarizine and dimenhydrinateÂ
this combination will make you feel sleepy or tired when Tranquillisers used in combination
cinnarizine and dimenhydrinateÂ
this combination will make you feel sleepy or tired when Tranquillisers used in combination
may decrease the level of serum concentration
tenofovir disoproxil fumarate or tenofovir DFÂ
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
When used with sedatives, eschscholzia californica can show addictive properties
it may reduce the therapeutic effect
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
Actions and spectrum
Frequency defined:
1-10%
Paresthesia
Vertigo
Dysarthria
Ataxia
Pediatric patients
Hyperactivity
Paradoxical excitement
Confusion
Excitement
Depression
Adverse effects that decrease with continued treatment
Ataxia
Headache
Nystagmus
Vertigo
Drowsiness
Irritability
Restlessness
Dizziness
Frequency Not Defined
Nausea
Megaloblastic anemia
Hypocalcemia
Osteomalacia
Stevens-Johnson syndrome
Acute psychosis
Vomiting
Diarrhea
Hepatotoxicity
Rickets
Rash
Black box warning:
primidone has been associated with an increased risk of suicidal thoughts and behaviour. This risk may be higher in patients with a history of depression or other psychiatric disorders.
Contraindications:
Caution:
Comorbidities:
Pregnancy consideration: category D
Lactation: primidone can be excreted in breast milk and can be harmful to nursing infants.Â
Pregnancy category:
Pharmacology:
The mechanism of action of primidone and its metabolites is not well understood, but it is believed to be related to their ability to increase the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits the activity of neurons in the brain. This results in a decrease in the excitability of neurons, which can reduce the occurrence of seizures.
Pharmacodynamics:
The pharmacodynamics of primidone are related to its effects on the central nervous system (CNS), where it acts as an anticonvulsant and antiepileptic medication. By enhancing the activity of GABA, primidone reduces the excitability of neurons, which can reduce the occurrence of seizures.
Pharmacokinetics:
Absorption: primidone is well absorbed from the gastrointestinal tract after oral administration. The time to reach peak plasma concentration is usually 3 hours.
Distribution: primidone is widely distributed throughout the body, and it crosses the blood-brain barrier to exert its effects on the central nervous system. It is approximately 20% to 25% bound to plasma proteins.
Metabolism: primidone undergoes hepatic metabolism, primarily via the cytochrome P450 system. It is metabolized to its active metabolites, phenobarbital and phenylethylmalonamide (PEMA), both of which have anticonvulsant properties.
Elimination: primidone and its metabolites are primarily eliminated by the liver and excreted in the urine. The elimination half-life of primidone is approximately 10-12 hours.
Administration:
primidone is usually administered orally in the form of tablets. The tablets are typically taken with or without food, and they should be swallowed whole with a glass of water.
The dosage of primidone is usually determined based on the patient’s weight and the severity of their condition. The medication is typically administered in divided doses, with the goal of maintaining a therapeutic level of the medication in the bloodstream.
Patient information leaflet
Generic Name: primidone
Pronounced: (prim-i-done)
Why do we use promidone?
primidone is an anticonvulsant medication that is primarily used to treat seizures, including partial seizures and generalized tonic-clonic seizures. It is used in the treatment of essential tremor, a neurological disorder characterized by involuntary shaking of the hands, head, and voice.
In the treatment of seizures, primidone is often used in combination with other anticonvulsant medications to help control the frequency and severity of seizures. It may also be used as a single therapy in some cases.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
